| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-115 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 | 1.基本情况 | | | --- | --- | | 信息披露义务人 | 2 孙小林 | | 住所 | 广东省珠海市香洲区情侣北路******** | | 权益变动时间 | 2025 年 2 月 13 日至 2025 年 12 月 8 日 | | | 1、公司第五期限制性股票激励计划回购注销限制性股票共计 | | | 2,017,966 股，回购注销涉及人数 51 人。经中国证券登记结算 | | | 有限责任公司深圳分公司审核确认，公司本次回购股份注销事宜 | | | 已于 2025 年 7 月 22 日办理完成。具体内容详见公司于 2025 年 | | | 7 月 22 日在巨潮资讯网（http://www.cninfo.com.cn）披露的 | | | 《关于部分限制性股票回购注销完成的公告》（公告编号： | | | 2025-054）。导致信息披露义务人持股 | | | 2、公司可转债 ...

本部分所述词语或简称与本核查意见"释义"所述词语或简称具有相同含义。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购管理 办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收 购报告书》等法律法规及规范性文件的有关规定，广发证券股份有限公司按照行 业公认的业务标准、道德规范，本着诚实信用和勤勉尽责的原则，对信息披露义 务人出具的《详式权益变动报告书》所披露的内容出具核查意见。 广发证券股份有限公司关于 北京九强生物技术股份有限公司 详式权益变动报告书 之 财务顾问核查意见 二〇二五年十二月 声 明 本财务顾问特作如下声明： 1、本财务顾问及信息披露义务人与本次权益变动行为之间不存在任何关联 关系，亦未委托或授权其他任何机构或个人提供未在本核查意见中列载的信息和 对本核查意见做任何解释或者说明。 2、本核查意见依据的文件、资料及其他相关资料由信息披露义务人提供。 信息披露义务人已做出承诺，保证其所提供的信息和文件真实、准确、完整，不 存在任何重大遗漏、虚假记载或误导性陈述，并对其真实性、准确性、 ...

证券日报网讯 12月4日晚间，九强生物发布公告称，公司于近期收到中华人民共和国国家知识产权局颁 发的1项专利证书及日本专利局颁发的1项专利证书，专利号分别为ZL202530087820.8和7771404，专利 名称分别为"化学发光免疫分析仪（Gi9000系列全自动）"和"基于反应曲线的曲率检测待检测样本的前 带现象的方法和装置"，专利权人均为九强生物，授权日期分别为2025年11月28日和2025年11月7日。上 述专利证书的取得不会对公司近期生产经营产生重大影响，但有利于发挥公司的知识产权优势，促进技 术创新，提升公司的核心竞争力，并形成持续创新机制。 （文章来源：证券日报） ...

证券日报网讯12月4日，九强生物（300406）在互动平台回答投资者提问时表示，公司相关产品通过CE 认证，为拓展欧洲业务奠定了核心基础，目前，公司产品已成功进入东欧、西欧多个国家和地区。未 来，公司将持续聚焦欧盟市场，进一步拓宽销售渠道、提升品牌影响力，为投资者创造更大价值。 ...

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-113 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司获得专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 1 项专利证书及日本专利局颁发 的 1 项专利证书，具体情况如下： | 序号 | 专利号 | 专利名称 | 专利权人 | 专利类型 | 申请日期 | 授权日期 | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | ZL202530 | 化学发光免 疫分析仪 | | | | | | | | 1 | 087820.8 | （Gi9000 系 | 九强生物 | | 外观设计2025.02.27 | 2025.11.28第 | 9659877 | 号 | | | | 列全自动） | | | ...

Core Viewpoint - The Biotech Economy Index (970038) closed at 2159.74 points on December 1, with a slight increase of 0.36%, indicating a stable performance in the biotech sector [1]. Group 1: Index Performance - The trading volume for the Biotech Economy Index was 14.616 billion yuan, with a turnover rate of 1.03% [1]. - Among the index constituents, 38 stocks rose, with Nine Strong Bio leading with a 4.43% increase, while 10 stocks fell, with Wens Foodstuffs leading the decline at 2.99% [1]. Group 2: Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price of 201.62 yuan, and a market cap of 244.45 billion yuan [1]. - Changchun High-tech (sz000661) with a weight of 4.87%, latest price of 100.09 yuan, and a market cap of 40.83 billion yuan [1]. - Other notable constituents include Kanglong Chemical (sz300759) and Muping Co. (sz002714) with respective weights of 4.55% and 3.62% [1]. Group 3: Capital Flow - On the same day, the net outflow of main funds from the index constituents totaled 18.3835 million yuan, while retail investors saw a net outflow of 66.8875 million yuan [3]. - Notable capital flows included: - Deep Technology (000021) with a net inflow of 16.216 million yuan from main funds [3]. - Wens Foodstuffs (300498) experienced a net outflow of 50.9861 million yuan from retail investors [3]. Group 4: Index Adjustments - Recent adjustments to the Biotech Economy Index included the addition of 9 new stocks and the removal of 9 stocks [3]. - New additions include: - Super Research Co. (301602) with a market cap of 9.783 billion yuan [4]. - Kanghua Bio (300841) with a market cap of 10.631 billion yuan [4]. - Stocks removed from the index include Wens Foodstuffs (300498) and Jingxin Pharmaceutical (002020) [4].

Market Overview - As of 10:31 AM today, the Shanghai Composite Index is at 3897.11 points, above the annual line, with a change of 0.22% [1] - The total trading volume of A-shares today is 9264.91 billion [1] Stocks Breaking Annual Line - A total of 99 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Guanghetong (14.08%) - Youji Co., Ltd. (8.85%) - Galaxy Electronics (8.67%) [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Guanghetong: Today's change of 14.94%, turnover rate of 16.55%, annual line at 27.18, latest price at 31.01 [1] - Youji Co., Ltd.: Today's change of 13.79%, turnover rate of 4.72%, annual line at 22.51, latest price at 24.50 [1] - Galaxy Electronics: Today's change of 9.92%, turnover rate of 9.87%, annual line at 5.20, latest price at 5.65 [1] Additional Stocks with Performance Metrics - Other stocks with significant performance include: - Emei Mountain A: Change of 10.02%, turnover rate of 8.44%, annual line at 13.35, latest price at 14.16 [1] - Yuzhong Three Gorges A: Change of 6.05%, turnover rate of 4.95%, annual line at 7.47, latest price at 7.89 [1] - Guanjie Technology: Change of 6.46%, turnover rate of 1.93%, annual line at 2.67, latest price at 2.80 [1]

Core Viewpoint - Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for its κ-Light Chain Assay Kit, which is intended for the quantitative measurement of κ-Light Chains in human serum [1] Group 1 - The product name is κ-Light Chain Assay Kit (Immunoturbidimetric Method) [1] - The expected use of the product is for in vitro quantitative measurement of κ-Light Chain levels in human serum [1] - The registration certificate is valid until November 23, 2030, from the date of approval [1]

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]

Core Viewpoint - Company has received a medical device registration certificate from the Beijing Drug Administration for the Kappa Light Chain (K-LC) assay kit, which is used for the quantitative measurement of K-LC in human serum, enhancing its product line in the in vitro diagnostic biochemical sector [1] Group 1 - The newly certified product is specifically designed for use with Abbott's closed-channel instruments, indicating a strategic partnership that may enhance market competitiveness [1] - This product expansion is expected to improve the company's core competitiveness and market expansion capabilities, potentially leading to positive impacts on future operations [1] - Actual sales performance of the product will depend on future marketing effectiveness, and the company currently cannot predict its impact on future financial performance [1]